Clarus Therapeutics Holdings Inc logo

Clarus Therapeutics Holdings Inc

$ 0.35 +0.02455 (+7.61%) 08:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 18.05M
Enterprise V:
$ 46.12M
Volume:
613.06K
Avg Vol (2M):
2.30M
Volume:
613.06K
Market Cap $:
18.05M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.30M
Enterprise Value $:
46.12M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Clarus Therapeutics Holdings Inc
NAICS : 325412 SIC : 2834
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Description
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Name Current Vs Industry Vs History
Cash-To-Debt 0.24
Equity-to-Asset -0.83
Debt-to-Equity -1.27
Debt-to-EBITDA -2.83
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -15.51
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 63.94
9-Day RSI 53.32
14-Day RSI 46.51
6-1 Month Momentum % -71.16

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.55
Quick Ratio 0.33
Cash Ratio 0.14
Days Inventory 2056.13
Days Sales Outstanding 201.32
Days Payable 2165.8

Dividend & Buy Back

Name Current Vs Industry Vs History

Financials (Next Earnings Date:2022-08-15 Est.)

CRXT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CRXT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 12.859
EPS (TTM) ($) -1.06
Beta 0
Volatility % 0
14-Day RSI 46.51
14-Day ATR ($) 0.029202
20-Day SMA ($) 0.313178
12-1 Month Momentum % 0
52-Week Range ($) 0.2605 - 9.77
Shares Outstanding (Mil) 52.02

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Clarus Therapeutics Holdings Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More